JPRN-UMIN000015982已完成2 期
Chemotherapy consists of Adriamycin and Ifosfamide for the patients with high grade primary bone sarcoma except for Ewing sarcoma over 41, Phase II trial - AI for bone sarcomas over 41-PII
Japanese Musculoskeletal Oncology Group; JMOG0 个研究点目标入组 35 人开始时间: 2015年1月10日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 35
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 41years-old 至 70years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Severe comorbid illness 2)Active infection 3)Synchronous or metachronous (within 5 years) malignancies 4)History of chemotherapy using ADR and/or IFO 5)Poorly renal or bladder function 6)Severe myelosuppression 7)Abnormal heart function 8)Patients having a pacemaker 9)Patients requiring pentostatin 10)Women in pregnant, possibly pregnant or breast feeding 11)Patients requiring systemic steroid medication 12)Psychiatric disease 13)Positive HBs antigen, HBs antibody, or HBc antibody
研究者
相似试验
进行中（未招募）
1 期
The benefit of adding drugs that stimulate the immune system to attack cancer to the standard treatment of colon cancer that has been removed surgically.Colon cancer stage IIIMedDRA version: 20.0Level: LLTClassification code 10009949Term: Colon cancer Duke's CSystem Organ Class: 100000004864EUCTR2017-000370-10-GBThe Royal Marsden NHS Foundation Trust402
进行中（未招募）
1 期
Chemotherapy with gemcitabine, capecitabine, irinotecan and bevacizumab to patients with cholangiocarcinoma after progression on first line treatment.patients with cholangiocarcinoma after progression. When patients with cholangiocarcinoma cannot be operated, we cannot cure them. The purpose of oncologic treatment is to prolong survival and to enhance quality of life. When first line treatment fails, we do not have a standard treatment for these patients. Many of the patients are still in a good condition and we hope for this group that our treatment can main stain their good condition and prolong survivalreatment.MedDRA version: 14.1Level: LLTClassification code 10008594Term: Cholangiocarcinoma non-resectableSystem Organ Class: 100000004864EUCTR2013-001559-11-DKHerlev University Hospital50
已完成
不适用
Treatment with standard chemotherapy and dendritic cells pulsed with WT1 peptides for pancreatic cancerunresectable pancreatic cancerJPRN-UMIN000032386The Jikei University School of Medicine, Kashiwa Hospital, Division of Gastroenterology & Hepatology, Department of Internal Medicine10
进行中（未招募）
1 期
enalidomide, Adriamycin, Dexamethasone (RAD)Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma followed by Response-adapted Consolidation and Lenalidomide Maintenance - A Randomized Multicenter Phase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)MedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2009-016616-21-DEWuerzburg University Hospital470
Unknown
不适用
Phase II Pilot Study of Vincristine, Adriamycin, Actinomycin D, Ifosfamide Combination Chemotherapy in Ewing's SarcomaEwing's SarcomaNCT00541411King Faisal Specialist Hospital & Research Center10